David Alan Kitzenberg

David Alan Kitzenberg, M.D., Ph.D. is a pharmaceutical research and infectious diseases expert specializing in the development of novel antibiotic adjuvants and strategies to combat antibiotic resistance. With a career encompassing biotechnology innovation, business strategy, and organizational leadership, he brings a cross-disciplinary perspective to litigation work. His work centers on investigating bacterial resistance mechanisms, assessing the efficacy of pharmaceutical interventions, and evaluating the impact of scientific advancements on treatment outcomes.

Mr. Kitzenberg has been retained in numerous expert witness and consulting engagements across the United States, involving cases related to pharmaceutical research, infectious diseases, and biotechnology startups. His Ph.D. in Molecular Biology, along with his M.D., reinforce his ability to deliver objective, defensible analyses. He is regularly engaged by both plaintiff and defense counsel to provide clear, independent determinations of causation in disputes involving bacterial infections and pharmaceutical efficacy.